AnaptysBio (ANAB) Investor Presentation - Slideshow

Pipeline and Catalysts - AnaptysBio's rapid antibody R&D engine has advanced 7 internally-generated antibodies to clinical development since 2016[4, 6, 8, 57] - Imsidolimab (ANB019, anti-IL-36R) GALLOP GPP Phase 2 Trial FDA End-Of-Phase 2 meeting is anticipated in Q4 2020[10, 59] - Imsidolimab (ANB019, anti-IL-36R) POPLAR PPP Phase 2 Trial top-line data is anticipated in Q1 2021[10, 59] - Imsidolimab (ANB019, anti-IL-36R) EGFRi Mediated Skin Toxicity Phase 2 Trial Phase 2 trial initiation in Q4 2020[10, 59] - Imsidolimab (ANB019, anti-IL-36R) Ichthyosis Phase 2 Trial Phase 2 trial initiation in Q4 2020[10, 59] - Etokimab (ANB020, anti-IL-33) ECLIPSE Adult Chronic Rhinosinusitis with Nasal Polyps Phase 2 Trial complete data is expected by year-end 2020[10, 59] - ANB030 (anti-PD-1 Agonist) Healthy Volunteer Phase 1 Trial top-line data is anticipated in mid-2021[10, 59] - ANB032 (anti-BTLA Modulator) IND Filing is anticipated in Q4 2020[10, 59] Financial Status - AnaptysBio has approximately $160 million in partnership revenues to date, with an additional $75 million in milestones anticipated in the upcoming 18 months, plus royalties[4, 53] - The company anticipates cash and existing partnerships to extend runway into 2023, with ~$375 million in cash (end Q3 2020) and a projected 2020 net burn close to breakeven[4]